🇯🇵·Apr 28Industry
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Publisher
O
Otsuka Holdings RSS
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Otsuka Holdings RSS
- Region
- Japan
- Scope
- Industry
- Published
- April 28, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on taiho.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Otsuka Holdings RSS
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences·21h ago
Company - Sellas Life Sciences
Hyman, Phelps & McNamara (FDA Law)·22h ago
WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage
Sumitomo Pharma·1d ago
Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia
Menicon·1d ago